With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion ...

Recursion’s study will initially address the recurrent C. diff (up to 175,000 cases in the US per year) population, which costs the healthcare system approximately US$2 billion per year. (US$1=RM4.32) ...

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions ...

Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.